drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Allogeneic, off-the-shelf T cells engineered with an anti-CD19 chimeric antigen receptor to target and eliminate CD19-expressing B-lineage cells, inducing transient B-cell aplasia to reduce autoantibody production and reset humoral immunity in refractory SLE.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic T cells engineered with an anti-CD19 chimeric antigen receptor recognize and kill CD19-expressing B-lineage cells. CAR engagement triggers T-cell cytotoxicity (perforin/granzyme) leading to depletion of CD19+ B cells and plasmablasts, inducing transient B-cell aplasia, reducing autoantibody production, and resetting humoral immunity in refractory SLE.
drug_name
CD19 Universal CAR-T cells
nct_id_drug_ref
NCT06691152